12 Best Mid-Cap Stocks with Huge Upside Potential

Page 9 of 12

4. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Analyst Upside: 45.34%

Market Capitalization: $7.75 billion

Number of Hedge Fund Holders: 46

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the best mid-cap stocks with huge upside potential. Truist Securities reaffirmed its Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and boosted its price target from $200 to $205 on August 28. The update comes after Jazz’s webcast, which focused on the company’s marketing approach for Modeyso (dordaviprone), a recently licensed medication that treats an extremely rare type of aggressive glioma with an H3 K27M mutation.

According to Truist Securities, Modeyso is well-positioned for “robust commercial uptake” in the market due to the lack of competition for this high-unmet-need brain tumor. Additionally, the firm noted that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was granted a Priority Review Voucher (PRV) for the clearance, whose estimated market worth exceeds $150 million.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company that develops treatments for serious illnesses. Its key products include Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos.

Page 9 of 12